215791-95-0

Basic information

• Product Name: tert-Butyl thiomorpholine-4-carboxylate
• Synonyms: tert-butyl 1,1-dioxothiomorpholine-4-carboxylate
• CAS NO: 215791-95-0
• Molecular Formula: C₉H₁₇NO₄S
• Molecular Weight: 203.30178
• Mol File: 215791-95-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 390.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.230±0.06 g/cm3(Predicted)
• PKA: -1.87±0.20(Predicted)
• CAS DataBase Reference: tert-Butyl thiomorpholine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl thiomorpholine-4-carboxylate(215791-95-0)
• EPA Substance Registry System: tert-Butyl thiomorpholine-4-carboxylate(215791-95-0)

Safety Data

• Hazardous Substances Data: 215791-95-0(Hazardous Substances Data)

Upstream product

• 220655-09-4 tert-butyl thiomorpholine-4-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 59801-62-6 1,1-dioxothiomorpholine hydrochloride 
• 39093-93-1 thiomorpholine 1,1-dioxide 

Downstream Products

• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 39093-93-1 thiomorpholine 1,1-dioxide 
• 59801-62-6 1,1-dioxothiomorpholine hydrochloride 

Relevant articles and documents

Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria

We previously discovered a series of novel biaryloxazolidinone analogues bearing a hydrazone moiety with potent antibacterial activity. However, the most potent compound OB-104 exhibited undesirable chemical and metabolic instability. Herein, novel biaryloxazolidinone analogues were designed and synthesized to improve the chemical and metabolic stability. Compounds 6a-1, 6a-3, 14a-1, 14a-3 and 14a-7 showed significant antibacterial activity against the tested Gram-positive bacteria as compared to radezolid and linezolid. Further studies indicated that most of them exhibited improved water solubility and chemical stability. Compound 14a-7 had MIC values of 0.125–0.25 μg/mL against all tested Gram-positive bacteria, and showed excellent antibacterial activity against clinical isolates of antibiotic-susceptible and antibiotic-resistant bacteria. Moreover, it was stable in human liver microsome. From a safety viewpoint, it showed non-cytotoxic activity against hepatic cell and exhibited lower inhibitory activity against human MAO-A compared to linezolid. The potent antibacterial activity and all these improved drug-likeness properties and safety profile suggested that compound 14a-7 might be a promising drug candidate for further investigation.

HETEROCYCLIC COMPOUNDS

Provided herein are compounds of formula (I) which comprise a thiomorpholine 1,1-dioxide or 1-imino-thiomorpholine 1-oxide moiety, or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including salts of the compound) and methods of synthesizing the same. Also provided are methods of treating Hepatitis B viral (HBV) infections using a compound of formula (I), or pharmaceutically acceptable salts thereof.

Neurotrophic factor tyrosine kinase receptor inhibitor

The invention provides a neurotrophic factor tyrosine kinase receptor inhibitor. The tyrosine kinase receptor inhibitor provided by the invention has a tricyclic parent core structure, can inhibit theactivity of Trk kinase and can be used for treating mammalian diseases mediated by the Trk kinase.